ArticleBMC cancer2025
The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant chemotherapy is the standard form of care for resected pancreatic cancer (PC) patients. Its treatment regimens include monotherapy with gemcitabine or S-1 and combination therapy with gemcitabine plus capecitabine or modified FOLFIRINOX (fluorouracil, oxaliplatin, irinotecan, leucovorin). Whether the efficacy of the adjuvant gemcitabine plus S-1 (GS) combination is realized remains uncertain.
methodsThis single-institute, retrospective, real-world study included 122 patients with resected PC from the period January 2014 to July 2021. Amongst them, 73 patients received adjuvant chemotherapy, with 21 and 35 patients receiving gemcitabine monotherapy and GS combination adjuvant chemotherapy, respectively. The clinical characteristics, outcomes and toxicities of chemotherapy were compared between these two groups.
resultsThe disease-free survival (DFS) and overall survival (OS) for the patients who had received GS combination were 15.8 months and 31.2 months, respectively. Compared with gemcitabine monotherapy, there was a trend towards favorable DFS (10.7 months in gemcitabine monotherapy, p = 0.083), but no OS benefits (24 months, p = 0.517) with GS combination. However, for patients in an advanced disease condition (Stages II and III), the GS combination offered statistically significant longer DFS (14.9 vs. 8.8 months; p = 0.015) and OS (31.2 vs. 21.6 months; p = 0.036), when compared with gemcitabine monotherapy. The adverse effects were comparable between the two groups.
conclusionsIn our real-world study, use of the GS combination could be another option for resected PC patients, particularly for those who are in a more advanced (Stage II and III) disease condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.